Identification of HER2 amplification by NGS in HER2-positive invasive breast carcinomas with negative HER2 IHC results would provide the opportunity for potentially beneficial anti–HER2-targeted therapies. The gene discussed is ERBB2; the disease is invasive breast carcinoma.